{
    "organizations": [],
    "uuid": "ed4089d6c21af7ffdf786855cf7fd0a933aa2ea3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-recipharm-q4-ebitda-at-sek-226-mil/brief-recipharm-q4-ebitda-at-sek-226-million-idUSFWN1QC027",
    "ord_in_thread": 0,
    "title": "BRIEF-Recipharm Q4 EBITDA At SEK 226 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - RECIPHARM AB (PUBL):\n* Q4 NET SALES SEK 1.40 BILLION VERSUS SEK 1.33 BILLION YEAR AGO\n* Q4 EBITDA SEK 226 MILLION VERSUS SEK 229 MILLION YEAR AGO\n* PROPOSES NO DIVIDEND FOR 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-22T14:52:00.000+02:00",
    "crawled": "2018-02-23T16:08:08.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "recipharm",
        "ab",
        "publ",
        "q4",
        "net",
        "sale",
        "sek",
        "billion",
        "versus",
        "sek",
        "billion",
        "year",
        "ago",
        "q4",
        "ebitda",
        "sek",
        "million",
        "versus",
        "sek",
        "million",
        "year",
        "ago",
        "proposes",
        "dividend",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}